Abeona Therapeutics Inc.
ABEO Nasdaq
SEC CIK 318306
Follow Abeona Therapeutics
Weekly email: filings, results
Revenue, last quarter
$13.5M
Net income
−$4.8M
+6.8% vs same quarter last year
EPS, diluted
−$0.08
+20% vs same quarter last year
Operating cash flow
−$8.3M
+60.8% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $5.8M | - |
| FY24 | - | - |
| FY23 | $3.5M | - |
| FY22 | $1.4M | −$39.7M |
| FY21 | $3M | −$84.9M |
| FY20 | $10M | −$84.2M |
| FY19 | - | −$76.3M |
| FY18 | $3M | −$56.7M |
| FY17 | $837K | −$27.3M |
| FY16 | $889K | −$21.9M |
| FY15 | $1M | −$14.5M |
| FY14 | $925K | −$26.8M |
| FY13 | $2M | $4.4M |
| FY12 | $4.4M | −$10.5M |
| FY11 | $1.8M | −$2.5M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 73.7% | −1536.9% | - |
| FY24 | - | - | - |
| FY23 | - | −1346.7% | - |
| FY22 | - | −3600.8% | −2807.4% |
| FY21 | - | −2994.5% | −2831.2% |
| FY20 | - | −814.2% | −842.3% |
| FY19 | - | - | - |
| FY18 | - | −1940.2% | −1890.3% |
| FY17 | - | −3325.7% | −3263.9% |
| FY16 | - | −2686.3% | −2460.4% |
| FY15 | - | −1783.3% | −1396.7% |
| FY14 | 100% | −338.5% | −2894.9% |
| FY13 | 93.9% | −186.3% | 217.9% |
| FY12 | 93.9% | −98% | −239.1% |
| FY11 | 92% | −428.3% | −137.7% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$84.3M |
| FY24 | −$58.5M |
| FY23 | −$37.3M |
| FY22 | −$43.6M |
| FY21 | −$69.8M |
| FY20 | −$36.4M |
| FY19 | −$69.1M |
| FY18 | −$48.4M |
| FY17 | −$23.5M |
| FY16 | −$13.5M |
| FY15 | −$10.7M |
| FY14 | −$1.6M |
| FY13 | −$1K |
| FY12 | −$4M |
| FY11 | −$7.6M |
- Abeona Therapeutics
- Healthcare median
Show the numbers
| Year | Abeona Therapeutics | Healthcare median |
|---|---|---|
| FY25 | - | −30.6% |
| FY24 | - | −47% |
| FY23 | - | −58% |
| FY22 | −2807.4% | −80.4% |
| FY21 | −2831.2% | −71.9% |
| FY20 | −842.3% | −62.2% |
| FY19 | - | −46.3% |
| FY18 | −1890.3% | −49.6% |
| FY17 | −3263.9% | −45.9% |
| FY16 | −2460.4% | −36% |
| FY15 | −1396.7% | −38.4% |
| FY14 | −2894.9% | −35.5% |
| FY13 | 217.9% | −37.1% |
| FY12 | −239.1% | −29.1% |
| FY11 | −137.7% | −27.9% |